Fundraising FoxAbingworth — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Founder)inFred Manby(Founder)inChao Zhang(Executive Officer)inTabbert Teng(Executive Officer)Neil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)in
Board seatKurt von Emster· per SEC Form D
Co-investorsAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+7 more
Pathalys Pharma is a biotechnology company developing and improving therapeutic treatments for patients with chronic kidney disease.
BiotechHealthtechResearch Triangle Park, US
BT Slingsby(Co-Founder & Executive Chairman)in
Co-investorsCatalys PacificOrbiMedSamsara BioCapitalKB Investment
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ascend Gene & Cell TherapiesNido Biosciences
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.